Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

2012467 citationsJournal Articlebronze Open Access

Authors

Harry D. Bear · Virginia Commonwealth University Medical Center

Gong Tang · University of Pittsburgh

Priya Rastogi · UPMC Hillman Cancer Center

Charles E. Geyer

André Robidoux · Centre Hospitalier de l’Université de Montréal

James N. Atkins · Wayne Community College

Luis Báez-Díaz

Adam Brufsky

Abstract

The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response, which was the primary end point of this study. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00408408.).

Topics & Keywords

Cancer Treatment and Pharmacology Breast Cancer Treatment Studies Chemotherapy-related skin toxicity

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 4, pp. 310-320

DOI: 10.1056/nejmoa1111097

Field-Weighted Citation Impact: 31.64